Atty Docket No.: 3284/1235 (Serial No.: 09/963,875)

Inventors: Habener, et al. Filed: September 26, 2001

Amendment Response to Office Action

Page 2

The following Listing of the claims will replace all prior versions and all prior listings of the claims in the present application.

Claims 1-38 and 44-73 are cancelled.

- 39. (Original) An isolated, nestin-positive human pancreatic or liver stem cell that is not a neural stem cell.
- 40. (Original) The isolated nestin-positive human pancreatic or liver stem cell of claim 39, wherein said cell is also GLP-1R-positive.
- 41. (Currently Amended) An isolated, GLP-1R-positive human pancreatic <u>or liver</u> stem cell that is not a neural stem cell.
- 42. (Original) The isolated, GLP-1R-positive stem cell of claim 41, wherein said cell is also nestin positive.
- 43. (Currently Amended) The isolated stem cell of claim 39 or 41 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.
- 74. (Currently Amended) A pharmaceutical composition comprising the isolated stem cell of claim 39 or 41 admixed with a physiologically compatible carrier.
- 75. (New) A method of isolating a stem cell from a pancreas, comprising the steps of:
  - (a) removing a pancreatic islet from a donor,
  - (b) removing cells from said pancreatic islet wherein said islet comprises a plurality of cell types comprising stem cells; and
  - (c) separating said stem cells from said plurality of cells.
- 76. (New) The method of claim 75, comprising the additional step of:

Atty Docket No.: 3284/1235 (Serial No.: 09/963,875)

Inventors: Habener, et al. Filed: September 26, 2001

**Amendment Response to Office Action** 

Page 3

- (d) expanding the nestin-positive cells by treatment with an agent selected from the group consisting of EGF, bFGF-2, high glucose, KGF, HGF/SF, GLP-1, exendin-4, IDX-1, a nucleic acid molecule encoding IDX-1, betacellulin, activin A, TGF-β, and combinations thereof.
- 77. (New) The isolated nestin-positive human pancreatic stem cell of claim 39, isolated by the method of claim 75.
- 78. (New) The isolated stem cell of claim 77 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.
- 79. (New) A pharmaceutical composition comprising the isolated stem cell of claim 77 admixed with a physiologically compatible carrier.
- 80. (New) The isolated nestin-positive human pancreatic stem cell of claim 41, isolated by the method of claim 75.
- 81. (New) The isolated stem cell of claim 41 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.
- 82. (New) The isolated stem cell of claim 80 that differentiates to form at least one of: insulin producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.
- 83. (New) A pharmaceutical composition comprising the isolated stem cell of claim 41 admixed with a physiologically compatible carrier.
- 84. (New) A pharmaceutical composition comprising the isolated stem cell of claim 80 admixed with a physiologically compatible carrier.